drugset / Trial / NCT01825031

Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy

NCT01825031

RandomizedFactorialOpen-labelTreatment

Summary

A randomised controlled trial to investigate three methods to reduce early mortality in adults, adolescents and children aged 5 years or older starting antiretroviral therapy (ART) with severe immuno-deficiency. The three methods are: (i) increasing the potency of ART with a 12 week induction period using 4 antiretroviral drugs from 3 classes (ii) augmented prophylaxis against opportunistic/bacterial infections and helminths for 12 weeks (iii) macronutrient intervention using ready-to-use supplementary food for 12 weeks.

Timeline

Start
2013-06
Primary completion
2016-03
Completion
2016-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Albendazole Small molecule 400 mg
Subject Azithromycin Small molecule 500 mg
Subject Fluconazole Small molecule 100 mg
Subject Isoniazid Small molecule 300 mg
Subject Raltegravir Other / unclassified 400 mg